| | 115007-34-6 Basic information More.. |
| Product Name: | Mycophenolate mofetil | | Synonyms: | Mycophenolate mofetil###115007-34-6;MYCOPHENOLATE MOFETIL,98.0%~102%,ENTERPRISE STANDARD;AKOS 92025;4-HEXENOIC ACID,6-(1,3-DIHYDRO-4-HYDROXY-6-METHOXY-7-METHYL-3-OXO-5-ISOBENZOFURANYL)-4-METHYL-,2-(4-MORPHOLINYL)ETHYL ESTER;2-Morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-hex-4-enoate;Mycophenolate mofetil;Mycophenolate Mofetil（MMF）;Matimaikaofenzhi | | CAS: | 115007-34-6 | | MF: | C23H31NO7 | | MW: | 433.49 | | EINECS: | 680-628-5 | | Mol File: | 115007-34-6.mol |  |
Use
Mycophenolate mofetil (MMF), whose trade name is “Cellcept”, was developed by the American Syntex Company. It is the semisynthetic derivative of mycophenocli acid (MPA) which is separated out from the glycolysis product of mold Penicillin glaucum. Mycophenolate mofetil is reusable cytostatics who have a history of clinical application being more than 10 years. It is mainly used for the treatment of psoriasis. At late 1980s, animal experiments have confirmed that it can significantly prolong the survival time of the allogeneic transplanted organs such as kidney, heart and islet of rodents. Sollinger et al has successfully applied MMF to the treatment of anti-rejection reaction upon kidney transplant for the first time with a remarkable effect. FDA has approved officially for its registration in 1995 under the trade name “Cellcept”, making clinical applications been added into a new and effective immunosuppressant for prevention and treatment of rejection reaction.
- Mycophenolate mofetil
-
- US $0.00 / KG
- 2024-03-16
- CAS:115007-34-6
- Min. Order: 100g
- Purity: 98%+
- Supply Ability: 100kg
- Mycophenolate mofetil
-
- US $50.00 / kg
- 2023-09-05
- CAS:115007-34-6
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 20t
- Mycophenolate mofetil
-
- US $150.00 / kg
- 2023-08-09
- CAS:115007-34-6
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000tons
|
|
115007-34-6
Recommend Suppliers |
|